EyePoint Appoints Michael Campbell as Chief Commercial Officer

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) appointed Michael Campbell as Chief Commercial Officer effective Feb 18, 2026. Mr. Campbell brings over 30 years of commercial leadership in retinal disease and will lead commercial strategy and launch readiness for DURAVYU (vorolanib intravitreal insert), currently in Phase 3.

The company granted an inducement award of 175,000 stock options with a four-year vesting schedule; options use the Feb 17, 2026 closing price as the exercise price.

Positive

• Michael Campbell: over 30 years retinal commercial experience
• Topline data for DURAVYU expected mid-2026

Negative

• Inducement grant: 175,000 stock options vesting over four years

News Market Reaction – EYPT

-3.69%

10 alerts

-3.69% News Effect

+5.9% Peak in 21 hr 40 min

-$48M Valuation Impact

$1.25B Market Cap

1.0x Rel. Volume

On the day this news was published, EYPT declined 3.69%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.9% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $48M from the company's valuation, bringing the market cap to $1.25B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Experience in retinal disease: over 30 years Development phase: Phase 3 Inducement option grant: 175,000 shares +3 more

6 metrics

Experience in retinal disease over 30 years Michael Campbell’s commercial leadership experience in retinal disease

Development phase Phase 3 DURAVYU development stage in wet AMD and DME

Inducement option grant 175,000 shares Stock options granted to Michael Campbell under Nasdaq Listing Rule 5635(c)(4)

Initial vesting tranche 25% Portion of inducement stock options vesting on first anniversary of grant

Vesting period 4 years Inducement stock options vesting schedule through the fourth anniversary

Franchise sale value $3.4 billion Sale of Xiidra ophthalmology franchise to Novartis referenced in Campbell’s background

Market Reality Check

Price: $15.33 Vol: Volume 8,719,925 is about...

high vol

$15.33 Last Close

Volume Volume 8,719,925 is about 5.95x the 20-day average of 1,465,458, indicating unusually heavy trading interest. high

Technical Shares at $14.91 are trading above the 200-day MA of $12.09, sitting 21.98% below the 52-week high of $19.11 and well above the 52-week low of $3.91.

Peers on Argus

EYPT gained 15.22% with strong volume, while only one tracked peer (QURE) appear...

1 Up

EYPT gained 15.22% with strong volume, while only one tracked peer (QURE) appeared in momentum scanners with a modest 2.25% move up and no same-day news, suggesting today’s move is stock-specific rather than a broad biotech or ophthalmology rotation.

Historical Context

5 past events · Latest: Feb 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Inducement option grants	Neutral	+15.2%	Inducement stock options totaling 143,000 shares granted to six new employees.
Feb 05	Conference participation	Neutral	+3.2%	CFO scheduled for fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
Jan 16	Inducement option grants	Neutral	-4.8%	Inducement options for 13,900 shares granted to three new employees under Nasdaq rules.
Jan 07	Corporate/milestone update	Positive	+3.0%	Corporate update on DURAVYU Phase 3 enrollment, timelines, and cash runway into Q4 2027.
Dec 17	Conference participation	Neutral	-1.6%	CEO presentation scheduled for the 44th Annual J.P. Morgan Healthcare Conference.

Pattern Detected

Recent news—mainly corporate updates, conference appearances, and inducement grants—has generally been followed by modest, mostly positive price moves, indicating the name has been responsive to corporate communication.

Recent Company History

Over the past two months, EyePoint’s news flow has focused on corporate visibility, option inducement grants, and pivotal progress for DURAVYU. A Jan 7 corporate update outlined Phase 3 enrollment completion, upcoming topline wet AMD data in mid-2026, and cash runway into Q4 2027, with shares up 3.02%. Conference announcements in December and February saw small price changes, while prior inducement option grants produced mixed but contained reactions. Today’s CCO appointment extends this pattern of execution-focused updates around DURAVYU’s commercialization path.

Market Pulse Summary

This announcement underscores EyePoint’s focus on commercialization by adding a Chief Commercial Off...

Analysis

This announcement underscores EyePoint’s focus on commercialization by adding a Chief Commercial Officer with extensive retinal disease launch experience, including Lucentis and Xiidra. It ties directly to DURAVYU’s Phase 3 program in wet AMD and DME and anticipated topline data in mid-2026. Recent filings show active use of equity incentives and insider transactions, while prior corporate updates highlighted enrollment completion and cash runway into Q4 2027. Investors may watch upcoming Phase 3 data, additional hires, and equity awards for further execution signals.

Key Terms

wet age-related macular degeneration, wet amd, diabetic macular edema, intravitreal, +3 more

7 terms

wet age-related macular degeneration medical

"currently in Phase 3 development for wet age-related macular degeneration (wet AMD) and diabetic"

A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.

wet amd medical

"Phase 3 development for wet age-related macular degeneration (wet AMD) and diabetic macular"

Wet AMD (wet age-related macular degeneration) is an eye disease in older adults where abnormal, leaky blood vessels grow under the retina and cause rapid vision loss in the center of the visual field. It matters to investors because it creates a sustained market for treatments, diagnostics and devices: changes in diagnosis rates, new drugs, or reimbursement rules can quickly affect healthcare revenues and the valuation of companies working on therapies.

diabetic macular edema medical

"development for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME)."

Diabetic macular edema is an eye condition in which fluid leaks into and swells the macula, the part of the retina used for sharp, central vision, often as a complication of diabetes. For investors it matters because it drives demand for medicines, medical devices and eye-care services, influences clinical trial and regulatory outcomes, and can affect healthcare costs and revenue forecasts—think of the macula as the camera’s central lens that becomes blurred when it soaks up excess fluid.

intravitreal medical

"launch readiness for DURAVYU™ (vorolanib intravitreal insert), currently in Phase 3 development"

An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.

anti-vegf medical

"Lucentis®, the first anti-VEGF treatment approved for wet AMD."

Anti-VEGF describes medicines or treatments that block a protein called vascular endothelial growth factor (VEGF), which tells the body to grow new blood vessels. By shutting off that signal, these therapies can slow or stop unwanted vessel growth and leaking in diseases such as certain eye disorders and cancers. Investors watch anti-VEGF programs because they can command large markets, affect patient outcomes, and drive drug sales, royalties, and valuation like controlling a major pipeline.

restricted stock units financial

"shares of common stock at $0.00 per share upon the vesting and settlement of previously granted restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"award material to Mr. Campbell entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –
– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis^® and Xiidra^® –

WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of prominent ophthalmology franchises, will assume responsibility for EyePoint’s commercial strategy and launch readiness for DURAVYU^™ (vorolanib intravitreal insert), currently in Phase 3 development for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Mr. Campbell will report directly to Dr. Jay S. Duker, President and CEO, and will serve on the executive leadership team.

“Mike is an accomplished commercial leader, and we are thrilled to welcome him to EyePoint at a truly transformational time for the Company,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “Mike brings a proven track record of successfully launching innovative ophthalmology products that revolutionized the retinal disease landscape, including the groundbreaking launch of Lucentis, which set the standard in retinal care. With topline data from our Phase 3 pivotal program in wet AMD expected beginning in mid-2026, his deep commercial expertise will be instrumental as we position DURAVYU for a successful U.S. launch as potentially the first sustained release TKI to market. Mike’s leadership and commercial expertise further strengthen our ability to execute, scale, and deliver new treatment options for patients.”

“I am excited to join EyePoint at a critical time and to be part of a Company that strongly aligns with my passion for bringing therapeutic innovation to patients,” said Mr. Campbell. “I am impressed with EyePoint’s de-risked, patient-centric approach to advancing its Phase 3 programs, including thoughtful trial designs that reflect real-world clinical practice and have the potential to support a compelling product label. With robust clinical data in both wet AMD and DME, a multi-mechanism of action, and as the only TKI in development for DME, DURAVYU offers significant commercial potential and the opportunity to emerge as the next gold standard in retinal disease treatment. I look forward to leveraging learnings from multiple launches in the retina market driven by innovation, precise execution, and patient focus to help position EyePoint for long-term success.”

Mr. Campbell brings to EyePoint over 30 years of commercial leadership experience, where he scaled global commercial organizations and pioneered patient-focused strategies for commercializing innovative ophthalmologic products.

Prior to joining EyePoint, Mr. Campbell was the Chief Commercial Officer at Opthea, where he built the commercial organization and led pre-launch readiness for a potential new product for the treatment of wet AMD. Previously, he served as Senior Vice President and Head of Commercial at Viatris Eye Care, where he led the commercial launch of Tyrvaya^®, the first nasal spray approved in dry eye disease. Mr. Campbell also contributed to the commercial planning of Beovu^® in wet AMD as Vice President of Biologic Commercialization in retina at Novartis and was the Vice President of the U.S. Ophthalmology Business Unit at Shire, where he led the sales, marketing and operations of Xiidra^® for dry eye disease and managed the transition of the franchise following the $3.4 billion sale to Novartis.

Mr. Campbell also held commercial leadership roles at Genentech, where he was a key leader in the commercial launch of Lucentis^®, the first anti-VEGF treatment approved for wet AMD. In these roles, Mr. Campbell not only designed the commercial structure, incentive model, reimbursement strategy and field execution plan for one of the most successful launches in Genentech’s history, but also played a critical role in managing Lucentis’s lifecycle, including its expansion into DME and retinal vein occlusion (RVO).

Mr. Campbell also held various sales and commercial roles at Johnson & Johnson Vision Care, Eli Lilly, and AstraZeneca / Medimmune. He holds a Bachelor of Science degree from Auburn University and is an Executive Education graduate from the University of Pennsylvania, Wharton School of Business.

Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

In connection with the hiring of Mr. Campbell, the Compensation Committee of EyePoint’s Board of Directors granted stock options to purchase an aggregate of 175,000 shares of common stock as an inducement award material to Mr. Campbell entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing price of EyePoint's common stock on February 17, 2026, and will vest as follows: 25% on the first anniversary and monthly through the fourth anniversary of the date of grant, subject to the terms of grant.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Forward Looking Statements

EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding our clinical development and regulatory plans; our belief that DURAVYU^™ is well-positioned to be the first-to-market among all investigational sustained release treatments for wet AMD; our belief that DURAVYU is the only TKI in development for DME; our belief that DURAVYU is uniquely positioned to potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME as a sustained delivery therapy; our belief that DURAVYU’s potential real-world application in multiple retinal disease indications and established trial designs position DURAVYU for clinical and commercial success; our expectations regarding timing for commencement of DME clinical trial enrollment and the timing of the availability and release of wet AMD clinical data; our expected cash runway; our belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer; and our expectations regarding the timing and clinical development of our other product candidates, including EYP-2301; and other statements regarding the Company’s future plans, objectives, strategies and beliefs, as identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” or other words of similar meaning or the use of future dates.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the Company’s clinical development activities, including DURAVYU; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company’s product candidates; changes in the regulatory environment; disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA; changes in U.S. and international trade policies; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; our ability to obtain additional funding to support our clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the Company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. A more complete discussion of the risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, in our other filings with the Securities and Exchange Commission (SEC) and in our future reports to be filed with the SEC, which are available at www.sec.gov. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Green Room Communications 
Direct: 850-384-2833
EyePointMedia@grcomms.com

FAQ

Who is Michael Campbell and what is his role at EyePoint (EYPT)?

Michael Campbell is EyePoint’s new Chief Commercial Officer, joining Feb 18, 2026. According to the company, he brings over 30 years of commercial leadership in retinal disease and will lead commercial strategy and launch readiness for DURAVYU.

What is the timeline for DURAVYU (vorolanib) Phase 3 topline data for EYPT?

Topline Phase 3 data for DURAVYU is expected beginning in mid-2026. According to the company, these pivotal results will inform U.S. launch readiness and regulatory planning for wet AMD and DME.

What are the terms of the inducement equity grant for EyePoint CCO Michael Campbell?

EyePoint granted Mr. Campbell an inducement award of 175,000 stock options with four-year vesting. According to the company, the exercise price equals the Feb 17, 2026 closing price and vests 25% after one year then monthly.

How might Michael Campbell’s experience affect EyePoint’s commercial readiness for EYPT shareholders?

Mr. Campbell has led multiple ophthalmology launches and will oversee launch readiness for DURAVYU. According to the company, his track record includes work on Lucentis and Xiidra, intended to strengthen commercialization capabilities.

To whom will the new CCO report and will he join EyePoint’s leadership team?

Michael Campbell will report directly to Dr. Jay S. Duker and join the executive leadership team. According to the company, he will assume responsibility for commercial strategy and U.S. launch readiness for DURAVYU.